Sellas Life Sciences Group Inc. held its Annual Meeting of Stockholders on June 17, 2025. Stockholders re-elected Angelos M. Stergiou and John Varian as Class III directors. The appointment of Baker Tilly US, LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2025, was ratified. An amendment to the 2021 Employee Stock Purchase Plan to increase the number of shares available for sale was approved. An adjournment of the meeting, if necessary, to solicit additional proxies in favor of certain proposals was also approved.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.